EXPERIENCE WITH SOFOSBUVIR IN TREATING HCV INFECTED PATIENTS IN TERTIARY CARE HOSPITAL KHYBER PAKHTUNKHWA

ABSTRACT
Objectives: To determine the efficacy and end therapy response of Sofosbuvir in HCV infected patients attending
tertiary care hospital.
Material and Methods: This observational study was conducted at Lady Reading Hospital MTI Peshawar from August
2016 to August 2017. All patients with Chronic Hepatitis C received Sofosbuvir 400mg plus weight based Ribavirin for
24 weeks. Follow up PCR was performed at end of treatment to determine ETR.
Results: A total of 135 patients were enrolled in the study. The mean age was 45.12 years (18.8 ± years).Out of 135
patients, 94(69.20%) were treatment naïve and 41(30.37%) patients were previously treated with interferon and RBV
combination. End therapy response (ETR) was 91.89 %( n=102) in genotype 3 while it was 91.66% (n =22) in patients
with genotype 1. Among 40 cirrhotic patients, end therapy response was achieved in 97.22% in genotype3, while it
was observed in 75.0% of genotype 1 patients.
Conclusion: Sofosbuvir in combination with Ribavirin is effectual and well tolerated in our population.